The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
DocD/ Fruits/ Et al:
Apologies for any ambiguity caused yesterday, to clarify:
From memory, Holgate has been researching into respiratory medicine for over four decades now, Synairgen were set up over two decades ago for the same reason. P2 should start before 30/06/24, but I estimate it will be at least two years from now before definitive P3 trial results will be released via a JV and we finally find out the true value of our investment.
20+ years is a generation, but that’s how long this process takes.
It takes time and time is not on our side. Anyone looking at the macro-economic picture will tell you there is another global crisis on the horizon and AIM shares don’t fare well in such an environment.
This did not start out as what some term ‘a covid share’ and it isn’t one now. SNG were blown off course by a once in a lifetime pandemic. Yes, funding came as a result, but I’m of the opinion that without covid, SNG would be 2-3 years closer to knowing how effective their course of treatment is in treating other respiratory conditions than they are now.
Covid/ Sars etc are transitory, but COPD and asthma are constant and that’s where the recurring income streams lie. These are the primary focus of GSK, they own 5 out of the top 10 selling respiratory drugs – Kerching.
As we wait ever so patiently for news, I was trying to impress that this whole process takes far longer than some members of this board realise or are willing to admit. I used TD’s quote merely as a starting reference, not to take sides.
I have absolutely no intention of getting in the middle of the long running three cornered spat that has been a feature of this board for over two years.
All three have provided valuable info/ insight in their own distinctive styles over the years.
I totally understand everyone is getting more than a little prickly now and I lay the reason for this firmly at Marsden’s door.
A breadcrumb trail, a bone to chew on, a mere morsel – Anything would be welcome at this stage. This isn’t a hand holding request, it’s normal corporate practise for the CEO to update shareholders on a quarterly basis as a bare minimum and RM has failed in his duty in this respect.
Hopefully our reticent CEO will deign to speak to those who are rattling their virtual pitchforks and lighted torches against the railings down in Southampton sooner rather than later, finally giving us a timeline for P2.
As always, ‘The Paladin’ summed the situation up nicely earlier this morning:
‘Last year, Simon Shaw spoke positively to investors and clearly stated that successful P2 outcomes would be likely to attract investment from BP companies.
Until we hear something to the contrary, this is what investors have been left with. The sooner that Synairgen add further clarity to their previous statement, the better it will be for all concerned.'
ATVB to genuine LTHs.
Good to see TommyD and DocD finally finding common ground yesterday.
Almost the equivalent of Putin and Biden shaking hands!
TommyD last month:
‘Generally developing a drug takes 10-15 yrs on average.’
Whatever your opinion of the poster TommyD, he is 100% correct when he says new drugs tend to take approx 15 years to develop.
This timeline is based on development by major pharmas, so a small research spin-off company like Synairgen will take even longer. Factor in another 2-3 years due to the disruption caused by covid and you’re looking at a timespan of 20+ years.
Here’s just a couple of examples relating to commonly used respiratory drugs:
Brown inhaler (beclomethasone) – First patent 1962 – First sale (USA) 1976 = 14 years.
Blue inhaler (salbutamol) – First patent 1966 – First sale (USA) 1982 = 16 years.
Blue inhaler is the 7th most prescribed drug in USA – 61 million sold last year.
Global patient numbers are massive, as are the profits.
It’s worth the wait.
The following link provides the numbers and shows why GSK are always looking over the shoulder of companies involved in respiratory research.
https://www.statista.com/statistics/1061043/top-asthma-medicines-sold-worldwide-by-revenue/
If SNG succeed this share will move North and fast.
If SNG fail, they will de-list from the stock exchange.
‘Trial and error’, but with the ‘error’ now largely factored in, this is no longer a 50/50 coin toss.
Not a share for the impatient or faint-hearted, but certainly compelling at this price.
Contrarian investing i.e. finding shares that are out of favour and undervalued can bring rich rewards, but you have to mentally prepare for the occasional loss now and again. If this does fail, you won’t hear any complaints from me, as no one told me to hit the ‘buy’ button.
I have the upmost respect for Sir David Jack, whose pioneering work led to the mass production of the commonly used inhalers listed above. These drugs changed the quality of my life, along with the lives of countless millions around the world.
I have the same respect for Sir Stephen Holgate, as without researchers of his ilk, new respiratory drugs would never be developed.
I for one hope that Sir Stephen’s decades of work come to fruition, for him, his colleagues and ourselves, but mainly for the millions of sufferers who are in desperate need of new treatments.
I guess we’ll find out within the next two years….If you can wait that long.
....invested/ genuine/ ill?
I'll leave you to decide.
‘Proven product’.…’Viable option’….OK, so you’re not reading these terms in a peer reviewed article in ‘The Lancet’….Yet. However, if you were one of the patients described below, you would certainly class yourself as ‘living proof’. These are just two examples of the type of patient SNG will be looking to treat in P2/P3.
Four years this week since my first investment here, in Spring 2020 this board had a similar feel as today. Only a small group of shareholders were posting, one or two were squabbling amongst themselves, along with a smattering of naysayers and damaged individuals sowing the seeds of doubt as per usual, as P2 trials were about to begin.
A couple of months passed when a link was posted, taking us to an image from a local paper of a smiling man surrounded by his family, from Melton Mowbray I think. A week earlier he was at death’s door on an ICU unit suffering from covid, but after trialling a new unnamed drug inhaled via nebuliser he made a remarkable recovery and went home early, virtually back to normal.
A couple of weeks later, another link appeared with a similar story, this time a woman from Hull had made a swift recovery from a position of little hope. Both were from SNG designated trial hospitals. This new trial drug was definitely ‘proven and viable’ in their eyes.
Investors started topping up, the share price rose from 20p – 50p within a couple of weeks as news spread, then multi-bagged during the summer when P2 results were released. Shares that were freely available around 35p in March were trading for well over 200p during August.
Four years later, we have a similar scenario, preparing P2 trials in order to reduce the time spent on ICU units.
With a specifically targeted cohort of patients (precision medicine), there is no reason why we shouldn’t see similar results.
I doubt there will be any mid-trial leaks this time, as covid is no longer a headline grabber and we won’t see exaggerated gains when the whole investment community seemed to be jumping from one covid stock to the other from week to week.
Even so, decent profits should be there for the taking for contrarian investors and LTHs may reach the nirvana of ‘break-even’ or better.
The current situation was succinctly summed up by ‘Doc83’ a couple of months ago:
‘To me, the plan is simple. Get the P2's underway, pass them, see a rerate in the SP and then partner up with BP for the P3. This is also what SS said to me post AGM.’
Holding an opposing view is fine, but you have to question the motives of those still present, who don’t think these trials will go ahead due to lack of funds or will fail due to lack of efficacy. If this is a dog share, why are they still here?
Waiting over two years for SNG to fail to say, ‘I told you so’ is a desperately sad way to spend your time, as is hovering over your keyboard in total isolation all weekend waiting for TD to post.
Are they inves
Fruits – With reference to ‘a large slice of the pie’:
This depends on an individual’s perception of the term ‘large’. You may consider a 33% slice as large, where another may view a 50/50 split as favourable, some would be content with losing 60% – We all have our own personal viewpoint of what is large. Obviously the quality of P2 results, the cash position, the resilience of the BOD during negotiations etc will be key in determining ‘the slice’, assuming we actually reach that stage.
I would imagine initial discussions will already have taken place to some degree behind closed doors.
Judging from most of the comments on here, investor fatigue is now well and truly entrenched. I suspect many individual retail investors would be relieved to see any type of JV and eventual takeover, in order to finally see SNG leave their portfolios. Playing ‘the long game’ takes patience, more so when a pandemic forces the ship to alter course for a couple of years.
Your link was an interesting read and shows how the BP view of minnows like SNG has altered over the years but even so, it has to be said the company is in a much weaker position post Sprinter with regard to negotiations going forward.
The future risk/ reward factor cannot be determined until we know the cash position/ P2 results/ TFG stance/ present BOD view etc.
As we move into Spring, I assume we’ll find out where we stand sooner rather than later. The highly contentious remark recently made on this board by Scinv (sorry, a freudian slip) by Sakura that ‘Interferons don’t work’ will be put to the test once again in due course.
If P2 results are favourable, those buying in at current levels may well make similar returns to those made back in the summer of 2020. Those who haven’t will be heavily reliant on Marsden + Co. negotiating a favourable deal.
Interesting to note that another AIM pharma research company with no commercial product readily available, recently spiked from 12p to 31p in less than two days on the back of promising, but not stellar results from a mere 67 patient trial, having drifted down from over 130p two years earlier.
I would imagine much bigger gains would be made in SNG’s case, given they have a proven product/ staff/ infrastructure ready to deliver if all goes to plan.
Pharma AIM shares are akin to playing high stakes snakes and ladders, especially when trial results are due. They’re not for the faint hearted or those with limited amounts of patience, especially when you have a CEO that likes to keep you guessing.
Whatever happens, I wish you and all genuine holders of this share all the very best going forward.
Spacman 08/01 @ 22.47: - ‘That’s me done here.’
If Only.
Reposting three previous contributions, in order to add a degree of respectability and reality back to the board this evening, in what has been another largely dismal week on here.
The Paladin:
‘Whatever happened to the sensible dialogue (positive and negative opinions) previously offered on this forum? Nowadays, it is a sea of green rectangles, sadly with otherwise sensible investors responding to them.’
DocD:
‘The funds will come from elsewhere - in exchange for a large slice of the pie. How large depends on how good the P2s are. Everything rests on the quality of patient selection. If they find the right 20 or 30 in each of the trials and the margin of improvement is stellar then the company will be back in business with a drug that looks almost certain to succeed its P3 provided the same parameters and metrics are used.
Best case scenario is something that replicates SG016's 79% in the much smaller but really important cohort of the most ill. If SNG can do something significant in this cohort it still has a future.
The commercialisation case will rest on savings to health systems rather than saving lives. Clearing the most ill from ICUs sooner…. Sending patients home in 5 days rather than 7 or 9.
That's why UNIVERSAL is so important. If it helps them develop the diagnostic tools to find the right triallists.’
Ghia:
‘There is a conflict of priority that the company is having to negotiate currently.
They want to design and run the perfect trials to maximise the opportunity to show the drug in a favourable light, which makes perfect sense.
To do this amongst other sources the data from universal will be crucial. Universal timing is out of their control to a large extent which is likely uncomfortable for the management team.
Conflicting with the need to run the right trial is the need to execute a trial within a specific time frame (before further funding is required). They have longer than most people are suggesting before this happens.
The only thing I’m confident of is they will run the right trial, but that means this takes priority over the timing which has factors outside of their control. This will take time.
Wishing all genuine investors a happy weekend.
T
They go away, keep falling into the trap and they stay - Your choice.
Today at 15.46:
‘On almost every bb there is a resident clown….’
I couldn’t agree more.
It should be crystal clear to long-term members of this board that this page has been infested by the constant rhetoric of two attention seeking narcissists, one antagonistic, the other a compulsive liar.
The second tells us on a regular basis that ‘the science is bad’, whatever that means.
This second individual has previously informed us that he:
• Was a former fund manager.
• Former senior ‘business insider’.
• Former professional trader.
• Had previous experience with SPACS.
• Makes ‘an easy £500 daily’ trading this share, even though the price barely moves from one week to the next.
• Has ‘a biotech guy’ who is also an institutional investor:
(30/01: ‘My biotech guy is an ii. Working at a specialised biotech firm with a good trackrecord.’)
• Has a business partner with access to 5 – 10 million to invest in SNG, even though in his words ‘the science is bad’.
(12/02: ‘And that is exactly why i have offered the company a solution as well (5-10mln)’)
• Would attend the last AGM if he could spare the time during a drinking weekend in London with his friends.
You would imagine that a man with such a background would now be a multi-millionaire and would spend his time anywhere but on a British penny share chat room.
You would also expect an individual from such an elevated position not to use foul and abusive language on three separate occasions towards fellow board members.
You would also think that a man with such an impressive track record would be able to string a sentence together in English, even though he claims to be from the Netherlands.
To coin a phrase from DocD, he ‘can barely write his own name in the sand with a stick’.
Here’s a selection of his latest offerings:
‘They promissed more communicstion at the AGM…’
‘I am not a legal expert myself but my lawyer has told me will be difficult they knew science.’
‘It should be easy to come up a P2. Unless we need all the bells and wissels because the science is not great’.
Definitely from the Netherlands, as his first language is clearly double dutch.
The latest from a string of misleading posts include:
06/02: ‘Fact: science not good enough’.
06/02: ‘Fact: TFG are in control. If they want out they can give me a call.’
£500 a day from trading – Seriously? I suspect the only thing this guy trades are pokemon cards.
This board reached a new low during the dark winter months when on 20/12 both narcissists attempted (and failed) at sensible dialogue with each other, causing the smart but rarely heard poster ‘Brysoa’ to comment:
‘11 filtered posts out of a possible 12 today so far. Is this a record?’
Yes Brysoa, I think it was.
Aether: ‘They don’t care what attention you give them as long as it is attention.’
Stop conversing with them and
Fruits - Succinct and to the point, I suspect you’re far from alone with that view….
Explains why last Tuesday’s most popular post of the day from ‘Meltonboy’ was:
‘Change the bloody record….’
January – We need an EGM.
February (8th) - ‘I think we will be fine even if we slip into H2’.
March – We need an EGM again.
Any detail on who will/ how to arrange such a meeting? – Don’t be silly.
What causes such swings in an individual’s thought process? Maybe the moon has now entered a different phase or the wind changed direction.... Or maybe they just post any old dross every day to draw attention.
£150k - Stop whining, that's peanuts - The investor formally known as Macosta, who now likes to be referred to as Mr 'working at haste' Costs has half a million shares - Think about how much he's lost.
Meanwhile on planet earth...
Marsden c'mon, you could put a stop to all this on our behalf....Care to say a few words?
Tomorrow at 7am would be a good time, remember 'we're very close to an RNS'.
Tommy –
‘We’re very close to an RNS’ – I hope that doesn’t come back to bite you, or have you had the nod? ;)
Happy to wait until 30th June for the latest P2 trials to start, but very unhappy with Marsden’s lack of updates/ comms in general. We could do with an update on how preparations for P2 are progressing.
This topic has been ‘done to death’, so let’s not rake over those particular coals yet again.
As we wait, it’s worth revisiting some facts to add a sense of realism to our current situation. The following is a reminder of how close SNG came to success. Close, but no cigar.
Apologies for not crediting the poster that gave us:
‘The P-value is an indication of the probability that the observed results occurred by chance.
By convention a P-value of 0.05 or less (a 5% chance it was a fluke, or 95% chance that it wasn't) is considered statistically significant. A P-value of 0.07 is considered to have too high a chance of having been achieved by fluke, and is therefore generally considered statistically insignificant.
It's quite a high bar.
With the small trial numbers it's very difficult to get to statistical significance. P=0.07 is pretty close.’
The next set of results only require a P-value reduction of 0.02 or better.
By selecting very specific target groups for P2, it is quite reasonable and logical to expect the next set of results to finally reach the nirvana of ‘statistical significance’. We can then look forward to a funded P3 via the safety net of a JV, however unfavourable the terms may be.
Credit to ‘Jint’ for crystallising the situation:
‘These diagnostic randomized clinical trials or test-treatment trials are considered the gold standard of proof for the clinical effectiveness or clinical utility of diagnostic tests.
Specific target patient group: 60+ yrs – hypertension – obese – auto-abs neutralizing type I IFNs in approx 10%.’
In other words, ‘precision medicine’.
Senior management, especially Monk and Brookes will have learnt valuable lessons from Sprinter, so the upcoming P2 trials will have to be virtually bullet proof, if not it will be a case of ‘Last one out, please turn the lights off.’
Better to start P2 as late as 30th June to give the best chance of success rather than risk failure once more.
As this is our final throw of the dice, I’m guessing the head honchos in Southampton are thinking the same.
I’ll leave you with a previous quote from Xviolet:
‘If you hadn't invested previously….the risk/reward case right now is quite something.’
At 5-6p, I agree.
Many thanks to those who offered kind messages of support recently, much appreciated.
Frustrating to see another prolonged spat breaking out as a result of my post, not what I intended. At the end of the day, we all want the same things:
successful trial results, another dramatic upturn in the share price and the safety net of a JV.
Much of the bickering on here is due to the prolonged period of silence from HQ, Marsden has created a vacuum that has a negative impact on both shareholders and share price.
One thing we can all agree on – We could do with some news, the sooner the better.
My counting beads tell me there are roughly 80 trading days left before the end of H1. With each passing day the clamour on here will get louder from the ‘usual suspects’.
C’mon RM, throw us a bone or throw us to the wolves.
Size82 –
Good to hear you’re still with us, as usual I agree with your latest post.
If I may, I’ll re-post one of your earlier offerings from my notes:
06/01/23:
‘The risk with a multi-virus trial is its complexity, and as Doc.Daneeka astutely points out we'd be starting at phase II. The Sprinter trial shows how something that was meant to be pretty bullet proof can fail. It's hard work.
We simply can't have another failure - we're practical toast as it is. Just look at the sp and the cash balance. If we get a second chance I really hope it's an inpatient trial specifically targeting those really struggling…. Synairgen need to make sure their next trial succeeds at any cost otherwise it will be their last.
It’s called risk management and if we're honest they didn't do a good job at protecting shareholder interests when investing our capital in the Sprinter trial. This simply can't happen again.
Running a trial under powered for secondary endpoint success is not good risk management. It was a massive oversight and I hope lessons have been learnt.’
Words that are as relevant today as they were over twelve months ago.
* Note to DocD – Thanks for sharing your story about your mum, much appreciated.
* Note to TommyD – I hope your cancer treatment brings some respite to your condition. I have prostate cancer myself, so I totally empathise with your situation.
ATVB T
Sorry to see my recent post was the catalyst for yet another unpleasant spat on this page. I apologise if I gave the impression that I was comparing outpatient drugs with SNG’s inpatient treatment on cost alone. Looking back I should have clarified this, as ‘fruits’ pointed out, inpatient against outpatient drugs can’t be compared. The prices quoted were merely for interest, showing how much various treatments cost these days.
The only comparison that really matters is the cost of SNG’s treatment v cost of daily ICU care.
Although I haven’t posted for eight months, I have read all contributions on a regular basis and it has been difficult to witness the six pillars of this page bickering and sniping at each other at regular intervals.
DocD, Doc83, Gunto, Fruitsnveg, TommyD + the master summariser The Paladin -
You fellas have kept the candle burning for many months now under difficult circumstances and all have contributed good insight/ info on a regular basis. I think the constant bickering and sniping is mainly frustration due to a lack of progress and prolonged silence from Marsden, hopefully he will give us all a bone to chew on in due course.
I have been reading this board since December 2019 and bought my first tranche of shares almost four years ago to the day in early March 2020.
Since that time I have been grateful to the following posters (and several others too many to mention) for providing valuable insight and opinion:
Matml74 – Schrow – Matterhorn – Dactions – Size82 – Prion – Beforegolf – Hanoihank – HelloSanDiego – Massive Ray – GGGG21 – Wpa5 – JoeyDiamond – HelloSanDiego – Ghia – Wigster – Doc83 – DocD – Hanoihank – Titania – Aether – Xviolet – Brysoa – Fruitsnveg – Wigster – Gunto – Jackman – Jint – Brand – TommyD (preferably the pre-crash version) – The Paladin (Formerly TL Williams).
I particularly miss the input from the first ten, who sadly no longer post here.
On the other side of the coin, the rogues’ gallery continues to grow:
Sangijuelas – Shadowboxer – Eva – Ndn71 – Burstead – Professional – Fanifesto – Scinv (returned as Scinv_temp) – Andybe4 – Macosta/ Mr Costs – Spacman.
I particularly miss Eva, who only posted at weekends, posing as a young woman from Malta with a glamourous lifestyle jetting around Europe, posting in broken English, who was actually a British male stringing along the gullible – most amusing at the time.
Our investment is now leading us into the complicated world of bio chemistry. Since my teens I’ve taken a keen interest in the workings of the respiratory system and associated drugs, but I have to confess my knowledge of auto-abs/ bio markers etc is limited to say the least. I doubt I’m not alone in this respect, I guess we’ll all be armchair experts by the end of the year. The saga continues….Hopefully not for another four years.
ATVB T
(cont from below)….
The ‘uncomfortable truth’ is the attraction isn’t about keeping chronically sick/ elderly patients alive for longer, it’s about saving money.
This is a discussion that will never take place in public by politicians or those holding the healthcare purse strings. Publicly admitting as much is hardly a vote winner is it?
Why do you think authorities were so slow to react when the elderly were dropping like flies in old folks homes during the height of the pandemic? Over stretched on resources, staff and budget, they were quitely letting nature take it’s course without actually saying as much.
4 Dexamethasone – the ‘low cost’ drug that killed our hopes, dreams and portfolios.
The decision to prescribe large doses of dex to acute covid patients proved to do more harm than good in the long run and would now only be given in moderation.
It’s worth revisiting previous contributions from two reliable posters to confirm:
Link posted by ‘Brand’ –
Peter Horby Tweet: ‘COVID-19 patients who require oxygen alone (not ventilation), a higher dose of corticosteroids (dexamethasone 20 mg once daily for 5 days followed by 10 mg once daily for 5 days) is harmful compared to low dose (dexamethasone 6mg daily).’
RECOVERY pre-print out. In hypoxic (low levels of oxygen in bloodstream) hospitalised COVID-19 patients requiring either no oxygen or simple oxygen only, higher dose corticosteroids significantly increased the risk of death compared to usual care, which included low dose corticosteroids.
The RECOVERY trial continues to assess the effects of higher dose corticosteroids in patients hospitalised with COVID-19 who require non-invasive ventilation, invasive mechanical ventilation or extra-corporeal membrane oxygenation.’
Also – ‘Prion25’:
‘The (over) use of steroids (dexamethasone) causes black fungus diseases because of immunosuppression whereas interferon beta does not.’
ICU patients with acute respiratory conditions are going to need an alternative.
The stakes couldn’t be higher.
DocD –
In light of your observations in your 10.12 post today, it’s worth taking another look at the current position regarding covid drugs. Maybe your family have first-hand anecdotal evidence regarding Paxlovid side effects?
1 Paxlovid – Side effects: Diarrhoea + vomiting are common, also does not mix well with 40 commonly prescribed medicines. £445 per course (Pfizer - USA).
2 Simnotrelvir – The latest trial drug with a component of Paxlovid called ritonavir, which helps to limit the breakdown of simnotrelvir. (Simcere - China).
Initially tested on more than 600 people with a median age of 35, around half of whom had at least one risk factor, such as obesity, for severe disease. None of the participants had severe COVID-19. By the fifth day after treatment, SARS-CoV-2 levels in participants who’d taken simnotrelvir had dropped by about 30-fold more than in participants who’d taken a placebo. No idea of cost, as this is still under trial.
Side effects: A notoriously bad taste and the same level of incompatibility with a range of common medication as Paxlovid.
3 Xocova (ensitrelvir) – Phase3 trials met both primary and secondary endpoints – EUA approval in Japan – Received fastrack status from FDA. Well tolerated with very limited side effects. £320 per course. (Shionogi - Japan).
Estimated 2 billion dollars annual sales.
Out of these three, which would you prefer?!
Looking to the future, it appears that Shionogi may well win the commercial battle with regard to a ‘mass market’ treatment for patients with mild covid symptoms.
This link gives an indication of the numbers involved in breakthrough drugs if you get your trials right
https://money.usnews.com/investing/news/articles/2023-02-27/shionogi-sees-covid-pill-reaping-2-billion-in-annual-sales-upon-u-s-approval
Obviously this is why Synairgen are now going down the ‘broad spectrum’ route and are now targeting the most vulnerable/ sick patients in an ICU setting.
The above three treatments need to be taken within three days of showing symptoms to be effective. Good luck with getting a GP appointment within this timescale in the UK. At least SNG are not faced with this issue.
Investors have been aware for some time that SNG no longer have a potential ‘cure all’ on their hands, the much quoted ‘it needs a fire to put out’ confirmed as much, but we do have a potential ‘niche drug’.
The kicker is the niche is more of a very large fissure, so it’s well worth persuing both medically and financially.
At over £1,000 per course (general consensus from conversations on this board during 2021), SNG’s drug is still attractive if P2/ P3 trials prove patients can leave ICU just one day earlier with no side effects.
The daily cost of an ICU bed in the UK was £1881 last March, so probably nearer £2,000 today.
https://www.theyworkforyou.com/wrans/?id=2023-03-14.165361.h
(cont above)…
Today at 15.18:
‘Ghia... Oh the irony of your post...Most likely lost on you..’
If the term ‘irony’ is lost on anyone, it is totally and completely lost on this severely flawed character.
Courtesy of my colleague’s files, here is only a small selection of accusations/ abuse aimed at other posters:
You are the aggressor, not me….
I think you are simply rude.....
You love to dish out insults on here, but are offended when you get some stick.....
…is just a disruptor, toxic and best ignored, attention seeking muppet!
You really don't fool anyone here with your constant presence ....
You spend a lot of time on here...... !!!
The ONLY thing you bring to this board is abuse......Take a break sweetie!!!
You are such a hypocrite and a delusional one at that !!
You must have repeated it a hundred times now.....
Your grammar is terrible....
….is an attention seeker....That ego takes a lot of feeding.
(The above was aimed at a poster with 2,200 posts – The accuser has 10,500+)
Three standout examples:
Give it a rest….
You are rude, arrogant and dismissive of anyone who does not concur with your view.
Your tone needs working on….
This continuous disorderly pattern of behaviour recently caused the smart, but rarely heard poster ‘Andrewcapp’ to comment,
‘Do you understand what a hypocrite is?’
Naturally, Andrew didn’t receive a reply.
A first year pyschology ‘A’ level student would politely point out to Andrew that this is not hypocrisy, but an easily recognisable trait termed ‘deflection’.
Here, the individual’s subconscious will attempt to deflect their own poor behaviour onto others, the conscious mind is totally unaware they are perfectly describing their own faults, at the same time making a complete fool of themselves in public.
All this from the creature who spent the best part of 2022 playing the back end of TommyD’s patomime horse, including countless ‘Well done Tommy’, ‘Thanks Tom!’ posts, now aggressively and compulsively disagreeing with every single post from this individual.
It is significant that intelligent male posters are always the prime object of aggression. You can be sure that there will be a strong underlying, deep rooted reason for this behaviour.
Why individuals like this are allowed to post on forums where people are trying to make serious decisions on where to invest their hard earned money is completely beyond me.
Irony…. Probably thinks it’s the warm metal plate that gets the creases out of your clothes.
To those of you who are frustrated by the constant pointless arguments created on this board on a daily basis, the link below will provide a clear insight into the reason. This was covered well over a year ago, but until the regulator takes action the problem will persist.
Due to staff cuts, most LSE boards are now poorly regulated, allowing this type of behaviour to flourish unabated.
The specific signs/ traits to look out for are:
Frequently posts the same repetitive viewpoint.
Overtly and constantly critical, frequently looking down on others.
Arrogance.
Lack of empathy.
Has difficulty managing emotions and behaviour.
Unreasonably high sense of self-importance.
Reacts with rage or contempt and attempts to belittle others, in order to make themselves superior.
Major problems interacting with peers and feel easily slighted.
Speaks excessively and dramatically with strong opinions, but with few accompanying facts.
You will easily recognise two individuals exhibiting this type of behaviour on this page alone. Their behaviour becomes more exaggerated over time, as they move along the spectrum with age.
The poster ‘Aether’, who tuned into this problem some time ago summed up the problem in one sentence at the end of last year.
‘They don’t care what attention you give them as long as it is attention.’
https://www.youtube.com/watch?v=KJy-YcuXgao
Spacman @ 15.19:
Professional, please can you elaborate on your comment:
"And that is exactly why i have offered the company a solution as well (5-10mln)"
Four hours later and still we wait for elaboration on this pivotal funding option, maybe he's in deep discussion with Marden (whoever that is).
Or maybe he's taken his medication and is currently incommunicado.
Or maybe he's taking part in a spelling bee.